Form 4: GRI Bio Director Acquires Stock Options

Camilla V. Simpson, a director at GRI Bio, Inc., acquired 30,297 stock options on January 23, 2025.

Summary

• Camilla V. Simpson, a director of GRI Bio, Inc., has reported the acquisition of 30,297 stock options.
• The transaction occurred on January 23, 2025.
• The exercise price of these options is $0.6857 per share.
• The options become exercisable on January 23, 2025, and expire on January 23, 2035.
• The options are for the purchase of 30,297 shares of common stock.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing and does not contain any information that would significantly impact sentiment positively or negatively.

Positives

• The acquisition of stock options by a director may indicate confidence in the company's future performance.

Industry Context

This is a standard SEC Form 4 filing, which is common for company insiders reporting transactions in their company's securities. It is a routine part of corporate governance and transparency.

Comparison to Industry Standards

• Stock option grants to directors are a common practice across publicly traded companies as part of their compensation and incentive programs.
• The terms of these options, such as the exercise price and expiration date, are typical for such grants.
• The reporting of these transactions via SEC Form 4 is a standard regulatory requirement for all US listed companies.

Stakeholder Impact

• The acquisition of stock options by a director may be viewed positively by shareholders as it aligns the director's interests with those of the company.

Key Dates

Keywords

stock options, GRI Bio, director, insider trading, equity, Camilla V. Simpson